{
    "nct_id": "NCT06024772",
    "official_title": "Prostate Cancer Diagnosis by Multiparametric Ultrasound (Clinical)",
    "inclusion_criteria": "* Subject must be scheduled for a prostate biopsy, based on an elevated PSA (> 3.0ng/ml) per most recent National Comprehensive Cancer Network (NCCN) guidelines, elevated PSA velocity (> 0.75ng/ml/year), or abnormal digital rectal examination\n* Subject must be able and willing to give written informed consent for a contrast enhanced ultrasound study of the prostate including the additional study biopsies\n* Subject must be a male at least 18 years of age when informed consent is obtained\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Participant in a clinical trial involving an investigational drug within the past 30 days\n* Patients with known or suspected hypersensitivity to perflutren, polyethylene glycol (PEG), or any other component of Definity\n* Previous treatment for prostate cancer, including hormone therapy\n* Clinically unstable, severely ill, or moribund as per treating physician",
    "miscellaneous_criteria": ""
}